| JANUARY | WEDNESDAY, JANUARY 23, 2019 | 9:00AM PT/12:00PM ET | EARLY PALLIATIVE CARE INVOLVEMENT IN BMT | KEVIN WEGERT, MD |
| FEBRUARY | WEDNESDAY, FEBRUARY 13, 2019 | 9:00AM PT/12:00PM ET | CAR-T CELLS: A PEDIATRIC PERSPECTIVE | JORG KUGLER, MD |
| MARCH | WEDNESDAY, MARCH 6, 2019 | 12:00PM PT/3:00PM ET | CURRENT MANAGEMENT OF WALDENSTROM MACROGLOBULINEMIA | JORGE J. CASTILLO, MD |
| APRIL | WEDNESDAY, APRIL 10, 2019 | 9:00AM PT/12:00PM ET | DRUG RELATED ISSUES IN BMT | LEO DUPUIS, RN, APTR, FCNP, RD |
| MAY | WEDNESDAY, MAY 22, 2019 | 12:00PM PT/3:00PM ET | GYNECOLOGICAL ISSUES POST-TRANSPLANT | MICHELLE JACOBSSEN, MD |
| JUNE | DATE & TIME TBD |  | COUNTING CD34+ CELLS IN THE CLINICAL TRANSPLANTATION SETTING: INTERESTING CASES AND IMPLICATIONS FOR ASSESSMENT OF GRAFT ADEQUACY | ROBERT SUTHERLAND, PHD, BSC, MD |
| SEPTEMBER | WEDNESDAY, SEPTEMBER 11, 2019 | 12:00PM PT/3:00PM ET | CONTROVERSIES IN USE OF HIGH DOSE CHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE GERM CELL TUMOR FOLLOWING CISPLATIN-BASED COMBINATION CHEMOTHERAPY | LAWRENCE FENTON, MD |
| OCTOBER | WEDNESDAY, OCTOBER 16, 2019 | 12:00PM PT/3:00PM ET | INTEGRATING cGvHD BIOMARKERS INTO THE CLINICAL EVALUATION OF cGvHD ACCORDING TO THE NATIONAL INSTITUTES OF HEALTH CONSensus CRITERIA | GEOFF CASSIVELLE, MD, FRCPC |
| NOVEMBER | WEDNESDAY, NOVEMBER 6, 2019 | 12:00PM PT/3:00PM ET | CELLULAR THERAPY MANUFACTURING – CLINICAL TRIALS AND HOPEs FOR THE FUTURE | DAVID COURTMAN, MD |

**WEBINAR SERIES**

**UPCOMING WEBINARS FROM CBMTG**

**MEMBERS PRICE:** FREE  
**NON-MEMBERS PRICE:** $90 + 5% GST PER WEBINAR

| JANUARY | WEDNESDAY, JANUARY 23, 2019 | 9:00AM PT/12:00PM ET | Early Palliative Care Involvement in BMT | Kevin Wegerten, MD |
| FEBRUARY | WEDNESDAY, FEBRUARY 13, 2019 | 9:00AM PT/12:00PM ET | CAR-T Cells: A Pediatric Perspective | Jorg Kugler, MD |
| MARCH | WEDNESDAY, MARCH 6, 2019 | 12:00PM PT/3:00PM ET | Current Management of Waldenstrom Macroglobulinemia | Jorge J. Castillo, MD |
| APRIL | WEDNESDAY, APRIL 10, 2019 | 9:00AM PT/12:00PM ET | Drug Related Issues in BMT | Leo Dupuis, RN, APTR, FCNP, RD |
| MAY | WEDNESDAY, MAY 22, 2019 | 12:00PM PT/3:00PM ET | Gynecological Issues Post-Transplant | Michelle Jacobsen, MD |
| JUNE | DATE & TIME TBD |  | Counting CD34+ Cells in the Clinical Transplantation Setting: Interesting Cases and Implications for Assessment of Graft Adequacy | Robert Sutherland, PhD, BSc, MD |
| SEPTEMBER | WEDNESDAY, SEPTEMBER 11, 2019 | 12:00PM PT/3:00PM ET | Controversies in Use of High Dose Chemotherapy in Patients with Progressive Germ Cell Tumor Followingcisplatin-Based Combination chemotherapy | Lawrence Fenton, MD |
| OCTOBER | WEDNESDAY, OCTOBER 16, 2019 | 12:00PM PT/3:00PM ET | Integrating cGvHD Biomarkers into the Clinical Evaluation of cGvHD According to the National Institutes of Health Consensus Criteria | Geoff Cassivelle, MD, FRCPC |
| NOVEMBER | WEDNESDAY, NOVEMBER 6, 2019 | 12:00PM PT/3:00PM ET | Cellular Therapy Manufacturing – Clinical Trials and Hopes for the Future | David Courtman, MD |

**Learning Objectives:**

**Wednesday, January 23, 2019**

1. Explore the relationship between Palliative Care and Bone Marrow Transplantation
2. Debunk myths regarding palliative care
3. Devise strategies for early palliative care involvement in BMT

**Wednesday, February 13, 2019**

1. Indications and Outcomes of CD19 CAR T-cell therapy in children with Acute Lymphoblastic Leukemia
2. Recognize and manage side effects and complications of CD19 CAR T-cell therapy
3. Access to CAR T-cell therapy for children with relapsed and refractory Acute Lymphoblastic Leukemia in Canada

**Wednesday, March 6, 2019**

1. Discuss the biology and pathogenesis of Waldenstrom macroglobulinemia
2. Review clinicopathological features of Waldenstrom macroglobulinemia
3. Provide an update treatment options in Waldenstrom macroglobulinemia, including the role of transplantation

**Wednesday, April 10, 2019**

1. Determine why and how we count CD34+ cells
2. Review how to develop International Guidelines
3. Discuss the importance of Single Platform approaches
4. Summarize sample-related analytic errors based on illustrative cases

**Wednesday, May 22, 2019**

1. Understand the rationale behind high dose chemotherapy with peripheral blood stem cell transplant
2. Appreciate the controversy of high dose versus standard dose salvage chemotherapy
3. Learn about managements of complications from high dose chemotherapy with peripheral blood stem cell rescue

**Wednesday, September 11, 2019**

1. How can we improve the risk assessment and evaluation of GVHD
2. How can we improve the risk assessment and evaluation of GvHD in clinical practice.
3. Discuss the importance of Single Platform approaches
4. Summarize sample-related analytic errors based on illustrative cases

**Wednesday, October 16, 2019**

1. Have an appreciation for the National Institutes of Health Consensus Criteria (NIH-CC) for Chronic GvHD evaluation, including the difference between diagnostic, distinctive, common, and other manifestations of GVHD, and how these can be applied to the classification and evaluation of GvHD in clinical practice.
2. Appreciate the benefits and challenges with the NIH-CC in evaluating cGvHD
3. Discuss how prognostic biomarkers may in the future be integrated into the risk assessment and evaluation of cGvHD.

**Wednesday, November 6, 2019**

1. To gain an understanding of the regulatory requirements for clinical cell processing for products involving more than minimal manipulation or intended for non-homologous use
2. Describe the infrastructure commonly used in cGMP manufacturing of experimental cell products.
3. Provide examples of clinical trial designs and outcome measures in advanced cell therapy trials.

**Wednesday, December 11, 2019**

1. Indications and Outcomes of CD19 CAR T-cell therapy in children with Acute Lymphoblastic Leukemia
2. Recognize and manage side effects and complications of CD19 CAR T-cell therapy
3. Access to CAR T-cell therapy for children with relapsed and refractory Acute Lymphoblastic Leukemia in Canada

**Wednesday, May 22, 2019**

1. Understand the rationale behind high dose chemotherapy with peripheral blood stem cell transplant
2. Appreciate the controversy of high dose versus standard dose salvage chemotherapy
3. Learn about managements of complications from high dose chemotherapy with peripheral blood stem cell rescue

**Wednesday, September 11, 2019**

1. How can we improve the risk assessment and evaluation of GVHD
2. How can we improve the risk assessment and evaluation of GvHD in clinical practice.
3. Discuss the importance of Single Platform approaches
4. Summarize sample-related analytic errors based on illustrative cases

**Wednesday, October 16, 2019**

1. Have an appreciation for the National Institutes of Health Consensus Criteria (NIH-CC) for Chronic GvHD evaluation, including the difference between diagnostic, distinctive, common, and other manifestations of GVHD, and how these can be applied to the classification and evaluation of GvHD in clinical practice.
2. Appreciate the benefits and challenges with the NIH-CC in evaluating cGvHD
3. Discuss how prognostic biomarkers may in the future be integrated into the risk assessment and evaluation of cGvHD.

**Wednesday, November 6, 2019**

1. To gain an understanding of the regulatory requirements for clinical cell processing for products involving more than minimal manipulation or intended for non-homologous use
2. Describe the infrastructure commonly used in cGMP manufacturing of experimental cell products.
3. Provide examples of clinical trial designs and outcome measures in advanced cell therapy trials.

The University of British Columbia Division of Continuing Professional Development (UBC CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide study credits for continuing medical education for physicians. This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by UBC CPD. You may claim a maximum of 15.0 hours (credits are automatically calculated). Each physician should claim only those credits he/she actually spent in the activity.